Isolere Bio by Donaldson announced on April 10, 2025, its participation in a $29 million contract awarded by the Advanced Research Projects Agency for Health (ARPA-H) to Ginkgo Bioworks and its partners. The project, named 'WHEAT' (Wheat-based High efficiency Enzyme and API Technology), aims to develop distributed manufacturing processes for essential medicines.
The WHEAT program focuses on utilizing wheat germ cell-free expression systems to produce biologic and small molecule active pharmaceutical ingredients (APIs). Isolere Bio by Donaldson will contribute its expertise to build innovative bioprocessing solutions, aiming to reduce costs and increase the speed of development for essential reagents and medicines.
This collaboration is designed to stabilize and reshore pharmaceutical supply chains by shifting API production from global dependencies to a robust, decentralized system. Isolere Bio's involvement underscores Donaldson's strategic expansion in the Life Sciences segment and its commitment to addressing critical healthcare challenges through advanced filtration and purification technologies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.